CERo Therapeutics Holdings, Inc. – NASDAQ:CERO

Add to watchlist

$8.44

+8.37

+13966.67%

Market open

Closed in about 3 hours

-69.26%

month

-69.26%

quarter

Market Cap	8.01M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO): Profit margin
2023	0	-2.53K

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO): Debt to assets
2023	8560610	22.75M	265.87%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO): Cash Flow
2022	-1.09M	180.83M	-138.70M
2023	-1.52K	-7.94K	-32.57K

CERo Therapeutics Holdings alternative data

CERo Therapeutics Holdings
Employees

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO): Employee count
May 2024	8
Jun 2024	8
Jul 2024	8
Dec 2024	8

CERo Therapeutics Holdings
Insider Trading

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO): Insider trades (number of shares)
Period	Buy	Sel
Sep 2024	0	532486
Oct 2024	0	3250000
Dec 2024	0	9615614

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	13 Dec 2024	YK BIOVENTURES OPPORTUNITIES GP I, LLC 10 percent owner 10 percent owner	Common Stock	2,998,908	$0.06	$179,934
Sale	12 Dec 2024	YK BIOVENTURES OPPORTUNITIES GP I, LLC 10 percent owner 10 percent owner	Common Stock	1,614,541	$0.07	$113,018
Sale	11 Dec 2024	YK BIOVENTURES OPPORTUNITIES GP I, LLC 10 percent owner 10 percent owner	Common Stock	1,343,801	$0.08	$107,504
Sale	10 Dec 2024	YK BIOVENTURES OPPORTUNITIES GP I, LLC 10 percent owner 10 percent owner	Common Stock	1,570,947	$0.09	$141,385
Sale	9 Dec 2024	YK BIOVENTURES OPPORTUNITIES GP I, LLC 10 percent owner 10 percent owner	Common Stock	850,543	$0.11	$93,560
Sale	6 Dec 2024	YK BIOVENTURES OPPORTUNITIES GP I, LLC 10 percent owner 10 percent owner	Common Stock	1,236,874	$0.12	$148,425
Sale	10 Oct 2024	YK BIOVENTURES OPPORTUNITIES GP I, LLC 10 percent owner 10 percent owner	Common Stock	3,250,000	$0.1	$325,000
Sale	25 Sep 2024	SLOAN STUART M 10 percent owner 10 percent owner	Common Stock, $0.0001 par value per share	532,486	$0.1	$55,379
Option	25 Sep 2024	LAPORTE KATHLEEN director director	Common Stock	965,997	$1,000	$965,997,000
Option	25 Sep 2024	LAPORTE KATHLEEN director director	Series A Convertible Preferred Stock	50	N/A	N/A

CERO insider trading transactions

CERo Therapeutics Holdings
Latest News

Friday, 6 December 2024
09:00	CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO	globenewswire.com
Friday, 15 November 2024
08:45	CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia	globenewswire.com
Monday, 11 November 2024
08:15	CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity	globenewswire.com
Monday, 21 October 2024
09:00	CERo Therapeutics, Inc. Provides Corporate Update	globenewswire.com
Wednesday, 2 October 2024
09:15	CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer	globenewswire.com
Wednesday, 25 September 2024
14:49	Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump	benzinga.com
09:17	CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236	globenewswire.com
Thursday, 13 June 2024
08:15	CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236	globenewswire.com
Wednesday, 15 May 2024
08:00	CERo Therapeutics, Inc. Provides Corporate Update for Shareholders	globenewswire.com

Frequently Asked Questions (FAQ)

What's the price of CERo Therapeutics Holdings stock today?

One share of CERo Therapeutics Holdings stock can currently be purchased for approximately $8.44.
When is CERo Therapeutics Holdings's next earnings date?

Unfortunately, CERo Therapeutics Holdings's (CERO) next earnings date is currently unknown.
Does CERo Therapeutics Holdings pay dividends?

No, CERo Therapeutics Holdings does not pay dividends.
How much money does CERo Therapeutics Holdings make?

CERo Therapeutics Holdings has a market capitalization of 8.01M.
What is CERo Therapeutics Holdings's stock symbol?

CERo Therapeutics Holdings, Inc. is traded on the NASDAQ under the ticker symbol "CERO".
What is CERo Therapeutics Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of CERo Therapeutics Holdings?

Shares of CERo Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does CERo Therapeutics Holdings have?

As Dec 2024, CERo Therapeutics Holdings employs 8 workers.
When CERo Therapeutics Holdings went public?

CERo Therapeutics Holdings, Inc. is publicly traded company for more then 3 years since IPO on 30 Nov 2021.
What is CERo Therapeutics Holdings's official website?

The official website for CERo Therapeutics Holdings is cero.bio.
Where are CERo Therapeutics Holdings's headquarters?

CERo Therapeutics Holdings is headquartered at 201 Haskins Way, South San Francisco, CA.
How can i contact CERo Therapeutics Holdings?

CERo Therapeutics Holdings's mailing address is 201 Haskins Way, South San Francisco, CA and company can be reached via phone at +65 04072376.

CERo Therapeutics Holdings, Inc.

cero.bio

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

+65 04072376

201 Haskins Way
South San Francisco, CA 94080

CIK: 0001870404
ISIN: US71902K1051
: